Jie Wu | Health and Medicine | Best Researcher Award

Published on by New Scientists

Prof. Dr. Jie Wu | Health and Medicine | Best Researcher Award

Professor and Lab Director, Shantou University Medical College, China

Prof. Dr. Jie Wu is a Distinguished Professor and Director of the Laboratory of Brain Function and Disease at Shantou University Medical College, China, and formerly served as Professor and Director of the Neurophysiology Laboratory at the Barrow Neurological Institute (BNI), St. Joseph’s Hospital and Medical Center, USA. He earned his M.D. from Xuzhou Medical College in 1983 and Ph.D. in Neurophysiology from Sun Yat-sen University of Medical Sciences in 1990, followed by postdoctoral fellowships at Tohoku University School of Medicine, Japan (1993–1994), and the University of New Mexico, USA (1994–1997). His research focuses on the physiology and pharmacology of nicotinic acetylcholine receptors (nAChRs), molecular mechanisms of epilepsy, and neurodegenerative disorders related to amyloid beta (Aβ) and receptor dysfunction, as well as ATP-sensitive potassium (KATP) channel regulation. Over three decades, he has led groundbreaking neuroscience research funded by the U.S. National Institutes of Health (NIH), the State of Arizona, and various international foundations, making fundamental discoveries in synaptic receptor signaling and neurodegeneration. His pioneering contributions have led to nearly 200 peer-reviewed publications, five book chapters, and eight patents (four U.S. and four Chinese), providing novel insights into receptor-mediated neurological diseases and translational therapies. Among his many honors, Prof. Dr. Jie Wu has received the China National Natural Science Award and the International HH Rosenfield Rekate Pioneer Award, and was listed among the World’s Top 2% Scientists (2022) and elected as a Fellow of the Royal Society of Arts (FRSA, UK, 2024). He serves as Editor-in-Chief and editorial board member for leading international journals and is active in global neuroscience and biomedical societies. With 161 documents, 5,887 citations and an h-index of 44, Prof. Dr. Jie Wu exemplifies research excellence and leadership, advancing global neuroscience through innovation, collaboration, and mentorship that continues to shape the future of brain science and human health worldwide.

Profile: Scopus | ORCID | Google Scholar | ResearchGate | Sci Profiles | Loop | LONGDOM | LinkedIn 

Featured Publications

1. Zhang, X. X., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J., Gardner, E. L., & Wu, J. (2014). Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America, 111(46), E5007–E5015.

2. Liu, Q., Huang, Y., Xue, F., Simard, A., DeChon, J., Li, G., Zhang, J., Lucero, L., & Wu, J. (2009). A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. Journal of Neuroscience, 29(4), 918–929.

3. Wang, T. N., Yang, W., Wang, Y., Nagaraj, V. J., Liu, Q., & Wu, J. (2012). Label-free measuring and mapping of binding kinetics of membrane proteins in single living cells. Nature Chemistry, 4(10), 846–853.

4. Chen, D. J., Gao, M., Gao, F. F., Su, Q. X., & Wu, J. (2017). Brain cannabinoid receptor 2: Expression, function and modulation. Acta Pharmacologica Sinica, 38(3), 312–316.

5. Okada, Y. C., Wu, J., & Kyuhou, S. (1997). Genesis of MEG signals in a mammalian CNS structure. Electroencephalography and Clinical Neurophysiology, 103(4), 474–485.

 

Paul Padovani | Health and Medicine | Best Researcher Award

Published on by New Scientists

Dr. Paul Padovani | Health and Medicine | Best Researcher Award

Pediatric cardiologist, University Hospital of Nantes, France

Dr. Paul Padovani is a Junior Doctor in Pediatric and Congenital Cardiology (MD, MSc in Clinical Research) at Nantes University Hospital (CHU de Nantes), France, where he integrates clinical practice, research, and digital health innovation to enhance outcomes for children with congenital heart disease. He earned his MD and MSc in Clinical Research, completing specialized cardiovascular medicine training after ranking 372nd in the French National Exam (ECN), with rotations in leading French university hospitals. His research focuses on pediatric and congenital interventional cardiology, quality-of-life assessment and exercise physiology in CHD, simulation-based medical education, and the development of AI/NLP pipelines integrated with OMOP Common Data Model (CDM) to enable structured healthcare data analysis. Professionally, he has contributed to over ten major research projects, including QUALISYSTEMIC, the first nationwide study on systemic right ventricle quality of life, and SIMUL-CHD, a randomized controlled trial on simulation-based communication training, while also leading AI-driven multicenter data initiatives. Dr. Paul Padovani has published 14 peer-reviewed articles, achieving 56 citations and an h-index of 4, reflecting his emerging impact in pediatric cardiology and digital health. He has received competitive research grants and recognition for advancing multicenter clinical studies and digital health programs. He is an active member of the French Society of Pediatric Cardiology (SFCP) and the Association for European Paediatric and Congenital Cardiology (AEPC), participating in international collaborations and peer-reviewed research efforts. His skills encompass clinical trial design, pediatric interventional procedures, simulation-based education, quality-of-life assessments, and AI-enabled data integration. Dr. Paul Padovani’s vision is to bridge clinical innovation, research, and education, improving patient outcomes, fostering reproducible research, and mentoring future leaders. His work is transforming pediatric cardiology, advancing digital health solutions, and establishing him as a globally recognized emerging leader in health and medicine.

Profile: Scopus | ORCID | ResearchGate | Sci Profiles | Scilit | LinkedIn

Featured Publications

1. Padovani, P., Singh, Y., Pass, R. H., Vasile, C. M., Nield, L. E., & Baruteau, A.-E. (2023). E-health: A game changer in fetal and neonatal cardiology? Journal of Clinical Medicine, 12(21), 6865.

2. Vasile, C. M., Padovani, P., Rujinski, S. D., Nicolosu, D., Toma, C., Turcu, A. A., & Cioboata, R. (2023). The increase in childhood obesity and its association with hypertension during pandemics. Journal of Clinical Medicine, 12(18), 5909.

3. Dardari, M., Iorgulescu, C., Bataila, V., Deaconu, A., Cinteza, E., Vatasescu, R., Padovani, P., Vasile, C. M., & Dorobantu, M. (2023). Transvenous lead extraction in a European low-volume center without on-site surgical support. Reports, 6(3), 41.

4. Dardari, M., Cinteza, E., Vasile, C. M., Padovani, P., & Vatasescu, R. (2023). Infective endocarditis among pediatric patients with prosthetic valves and cardiac devices: A review and update of recent emerging diagnostic and management strategies. Journal of Clinical Medicine, 12(15), 4941.

5. Padovani, P., Grunenwald Gronier, C., & Baruteau, A.-E. (2023). Midline crossing right pulmonary veins with dual drainage to the left atrium. Cardiology in the Young, 33(2), 305–308.

 

Xiaofeng Dai | Medicine Advances | Best Researcher Award

Published on by New Scientists

Prof. Xiaofeng Dai | Medicine Advances | Best Researcher Award

Professor at The First Affiliated Hospital of Xi’an Jiaotong University, China.

Prof. Dr. Xiaofeng Dai is a distinguished expert in precision oncology and plasma medicine, currently serving as Professor and Research Theme Leader at the First Affiliated Hospital of Xi’an Jiaotong University. With dual PhDs in Systems Biology (Genetics) and Econo-Informatics from Finland, she integrates interdisciplinary knowledge across molecular oncology, bioinformatics, and translational medicine. Prof. Dai has established herself as a global leader in exploring the molecular and clinical applications of cold atmospheric plasma (CAP) therapy, publishing over 114 SCI-indexed articles with a cumulative impact factor of 806.74. She is the first or corresponding author of all these works, including four ESI highly cited papers. Her scientific achievements are further marked by 2 U.S. patents, 4 Chinese invention patents, and 10 software copyrights. She has secured and led national and industrial research funding exceeding 10 million RMB. Recognized for her pioneering work, Prof. Dai has received prestigious honors including Academician of the European Academy of Natural Sciences (2023), Outstanding Engineer Award (2022), and selection in the Jiangsu Province 333 High-level Talents Program (2024). As an active contributor to academic societies and a passionate educator, she is committed to translating advanced research into tangible clinical innovations.

Publication Profile

Scopus

Educational Details

  • Ph.D. in Econo-informatics, Aalto University, Finland (2016)

  • Ph.D. in Systems Biology – Genetics, Tampere University of Technology, Finland (2010)

  • M.Sc. in Bioinformatics, University of Tampere, Finland (2010)

  • M.Sc. in Molecular Biology, Chinese Academy of Agricultural Sciences, China (2006)

  • B.Sc. in Biotechnology, Central South University of Forestry and Technology, China (2003)

Professional Experience

  • 2023/06 – Present: Professor, Theme Leader – Precision Oncology, The First Affiliated Hospital of Xi’an Jiaotong University

  • 2017/06 – 2023/05: Professor, Theme Leader – Precision Medicine, Jiangnan University

  • 2014/02 – 2017/05: Associate Professor, Precision Medicine, Jiangnan University

  • 2016/12 – 2017/02: Visiting Scholar, Queensland University of Technology (QUT), Australia

  • 2013/10 – 2014/01: Principal Investigator, Chinese National Human Genome Center

  • 2011/02 – 2013/09: Senior Research Fellow, Helsinki University Central Hospital, Finland

  • 2010/02 – 2011/01: Senior Research Fellow, Institute for Molecular Medicine Finland

  • 2007/03 – 2011/01: Research Fellow, Tampere University of Technology, Finland

Research Interest

Prof. Dai’s research centers on cold atmospheric plasma (CAP)-based therapies in oncology and beyond. Her interests lie in exploring the molecular underpinnings of CAP’s selective cytotoxicity against malignant cells, investigating its influence on cancer stemness, metastasis, and tumor microenvironment. Expanding from cancer, her current work includes the use of CAP in immunomodulation, metabolic disorders, viral prevention, and vaccine enhancement. She also focuses on developing innovative CAP delivery systems such as ingestible CAP capsules and CAP-mediated photodynamic therapy, aiming to enhance its versatility and applicability. Prof. Dai is also addressing key translational barriers—such as CAP’s short-lived reactive components—by designing storage-stable and sustained-release solutions. Her research integrates bioinformatics, molecular biology, and plasma physics to decipher therapeutic pathways and identify CAP-mimicking biomolecules. Through computational modeling and synthetic chemistry, she is developing molecules with CAP-like efficacy, pushing forward the concept of molecular plasma medicine. Her goal is to create clinically adaptable, precision-targeted, and minimally invasive treatment solutions across a wide spectrum of diseases.

Research Skills

Prof. Dai is proficient in a broad array of interdisciplinary research techniques, spanning molecular biology, plasma physics, bioinformatics, and translational medicine. Her core expertise includes the design and execution of high-throughput omics experiments, real-time plasma-matter interaction studies, and in vitro/in vivo cancer models. She is skilled in CRISPR-based functional genomics, computational modeling of plasma-induced cellular responses, and RNA-seq data interpretation. Her strong background in systems biology enables her to construct multi-scale models that integrate molecular, cellular, and clinical data. She has extensive experience in developing biomedical devices and software tools tailored to plasma applications, backed by 10 software copyrights. Her ability to secure industrial partnerships and government funding demonstrates her leadership in translational research. Additionally, Prof. Dai has led cross-disciplinary teams to develop CAP-based interventions for autoimmune diseases, metabolic disorders, and infectious disease prevention. She is also adept at scientific communication, grant writing, project management, and mentoring junior researchers and students.

Awards and Honors

Prof. Dai’s research excellence and leadership have been widely recognized. In 2024, she was named a Level 3 recipient in the prestigious “333 High-Level Talent Program” of Jiangsu Province. In 2023, she was elected an Academician of the European Academy of Natural Sciences, highlighting her international stature. Her innovative research earned her the Outstanding Engineer Young Award in 2022 from the International Scientific Exchange Foundation of China. Earlier honors include being a member of the Dual Innovative Team of Jiangsu Province (2017), receiving the Six Talent Peaks Award (2016), and being named a Leading Talent for Social Undertakings in Wuxi (2015). These accolades underscore her sustained contributions to scientific innovation, particularly in the interdisciplinary domains of bioengineering, oncology, and plasma medicine. They also reflect recognition by both national and international academic bodies, industry collaborators, and government agencies. Her ability to integrate science, education, and clinical translation has made her a respected figure in China’s high-impact research ecosystem.

Author Metrics

  • Total Citations: 4,522

  • Citations by Documents: 4,063

  • Total Publications (Documents): 125

  • h-index: 29

Top Noted Publication

1. Advanced Science (2020)

Title: Innovative precision gene-editing tools in personalized cancer medicine
Journal: Advanced Science

  • IF (2023): ~17.5

  • JCR Rank: Q1 (Multidisciplinary Sciences)

  • Reason: Highly impactful, interdisciplinary, cutting-edge gene-editing research published in a top-tier journal.

2. Trends in Biotechnology (2018)

Title: The emerging role of gas plasma in oncotherapy
Journal: Trends in Biotechnology

  • IF (2023): ~20.0

  • JCR Rank: Q1 (Biotechnology & Applied Microbiology)

  • Reason: Published in a Cell Press journal, which is highly selective. Recognized for trend-setting reviews.

3. Signal Transduction and Targeted Therapy (2025)

Title: Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics
Journal: Signal Transduction and Targeted Therapy

  • IF (2023): ~39.3

  • JCR Rank: Q1 (Immunology/Oncology)

  • Reason: Nature Publishing Group journal with very high impact. Although recent, its publication in a Nature journal signifies top-tier status.

4. Trends in Genetics (2022)

Title: Histone lactylation: epigenetic mark of glycolytic switch
Journal: Trends in Genetics

  • IF (2023): ~12.0

  • JCR Rank: Q1 (Genetics & Heredity)

  • Reason: Cell Press review journal with major influence in the field of epigenetics and gene regulation.

5. Biotechnology Advances (2019)

Title: Standardizing CAR-T therapy: getting it scaled up
Journal: Biotechnology Advances

  • IF (2023): ~14.2

  • JCR Rank: Q1 (Biotechnology)

  • Reason: Authoritative journal in biotechnology with strong clinical and commercial relevance, especially in CAR-T research.

Conclusion

Prof. Dr. Xiaofeng Dai is a leading interdisciplinary scientist advancing cold atmospheric plasma (CAP) therapy in precision oncology and regenerative medicine. With dual Ph.D. degrees, over 100 SCI-indexed publications, and multiple patents, she bridges molecular research with clinical application. Her leadership in securing major research funding and fostering industry collaboration highlights her impact across science and innovation. As an educator and mentor, she is shaping future experts in cancer biology and bioinformatics. Through national and international partnerships, Prof. Dai remains at the forefront of translating high-impact research into real-world medical solutions.